Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

Core Points - Provectus Biopharmaceuticals, Inc. will hold its 2025 annual stockholder meeting on June 18, 2025, at the Hilton Knoxville, accessible via Zoom Webinar [1][2] - The meeting will include shareholder activities and a company update, starting at 4:00 p.m. Eastern Time [1] - Annual Meeting materials are available on Provectus's website, including the Proxy Statement and 2024 Annual Report [2] Company Overview - Provectus is a clinical-stage biotechnology company focused on developing immunotherapy medicines using synthetic small molecules known as halogenated xanthenes [3] - The lead molecule of the company is Rose Bengal Sodium [3] - The company's medical science platform encompasses clinical development in oncology, dermatology, and ophthalmology, along with various proof-of-concept programs [4] Clinical Trials and Research - Information regarding the company's clinical trials can be accessed through the National Institutes of Health registry, ClinicalTrials.gov [5]